Evidence map›Paper›PMID 42778832›Full record

ArticleBulletin of experimental biology and medicine2026

Comparison of Cell Line-Derived and Patient-Derived Xenograft Technologies in Oncology (Review).

E A Gantsova, I V Arutyunyan, G D Perevyazkina, K B Gordon, T Kh Fatkhudinov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

E A GantsovaResearch Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia. gantsova@mail.ru.
I V ArutyunyanResearch Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia.
G D PerevyazkinaResearch Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia.
K B GordonResearch Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia.
T Kh FatkhudinovResearch Institute of Molecular and Cellular Medicine, Peoples' Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The review evaluates the potential of preclinical in vivo modeling of human tumors. Two fundamental xenograft technologies, cell line-derived xenograft (CDX) and patient-derived xenograft (PDX), are described and their roles within the established methodological framework of translational biomedicine are characterized. The discussion covers practical aspects of model creation and the role of immunodeficient animals in the evolution of cancer modeling. Original data and the results of other research groups obtained in the study of tumor xenografts are analyzed. A comprehensive assessment of the advantages and limitations of CDX and PDX tumor models suggests that they play complementary, rather than competing, roles in modern preclinical oncology.

Indexed as

immunodeficient animalsin vivo tumor modelingpersonalized medicinetranslational oncologyxenograft model

Identifiers

PMID42778832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.